Search results
Results from the WOW.Com Content Network
Ceftriaxone, sold under the brand name Rocephin, is a third-generation cephalosporin antibiotic used for the treatment of a number of bacterial infections. [4] These include middle ear infections, endocarditis, meningitis, pneumonia, bone and joint infections, intra-abdominal infections, skin infections, urinary tract infections, gonorrhea, and pelvic inflammatory disease. [4]
For ceftriaxone, the color of solutions can range from light yellow to amber, depending on the length of storage, concentration, and diluent used. [30] [31] A study found that meropenem concentrations dropped to 90% of the initial concentration at 7.4 hours at 22°C and 5.7 hours at 33°C, indicating degradation over time. [29]
Since August 2012, the third-generation cephalosporin, ceftriaxone, is the only recommended treatment for gonorrhea in the United States (in addition to azithromycin or doxycycline for concurrent Chlamydia treatment). Cefixime is no longer recommended as a first-line treatment due to evidence of decreasing susceptibility. [30] Ceftriaxone ...
Ceftriaxone (IV and IM, not orally, effective also for syphilis and uncomplicated gonorrhea) Rocephin: Cephalosporins (Fourth generation) Cefepime: Maxipime: Covers pseudomonal infections. Gastrointestinal upset and diarrhea; Nausea (if alcohol taken concurrently) Allergic reactions
Biliary pseudolithiasis is an unusual complication of ceftriaxone where the drug complexes with calcium and mimics gallstones. [1] [2] It is reversed when ceftriaxone administration is stopped. [2] It was first described in 1988 by Schaad et al. as "reversible ceftriaxone-associated biliary pseudolithiasis".
From Wikipedia, the free encyclopedia. Redirect page
The flu is ramping up after a slow start to the season. Positive tests rose 12% for the week ending Dec. 21, compared to the week prior, according to data released Friday by the Centers for ...
In a study comparing the safety and efficacy of levofloxacin to that of azithromycin or ceftriaxone in 712 children with community-acquired pneumonia, serious adverse events were experienced by 6% of those treated with levofloxacin and 4% of those treated with comparator antibiotics. Most of these were considered by the treating physician to be ...